We conducted a retrospective study of patients who had received kidney, liver, or heart transplant, had diabetes either pre-or post-transplant, and were treated with GLP-1RA. We identified seven kidney, seven liver, and five heart transplant recipients who had received GLP-1RA. We assessed changes in immunosuppressant levels, rejection episodes, changes in Hb A1c (HbA1c), weight, and body mass index (BMI) while on the GLP-1RA. We also looked at changes in insulin dose, other diabetes medications, heart rate, blood pressure, and renal function. Results: After a mean follow-up period of 12 mo, there were no significant changes in tacrolimus (FK506) levels and renal function for the period of GLP-1RA use. At the end of 12 mo, the mean drop in weight was 4.86 kg [95% CI-7.79, -1.93]. The BMI decreased by a mean of 1.63 kg/m2 at the end of 12 mo [95% CI-2.53, -0.73]. HbA1c decreased from baseline by 1.08% [95% CI-1.65, -0.51], 0.96% [95% CI-1.68, -0.25], and 0.75% [95% CI- 1.55, 0.05] at 3, 6, and 12 mo, resp. Conclusions: Our data suggest that GLP-1RA do not affect tacrolimus levels or transplant outcomes in solid organ transplant (SOT) recipients in the short term. GLP-1RA also seem to be as effective in SOT recipients for glycemic control and weight loss as in the non-transplant population with diabetes.